CERS
Price
$1.39
Change
+$0.03 (+2.21%)
Updated
Jul 25 closing price
Capitalization
342.62M
10 days until earnings call
XWEL
Price
$1.12
Change
-$0.08 (-6.67%)
Updated
Jul 25, 04:59 PM (EDT)
Capitalization
7.06M
Interact to see
Advertisement

CERS vs XWEL

Header iconCERS vs XWEL Comparison
Open Charts CERS vs XWELBanner chart's image
Cerus
Price$1.39
Change+$0.03 (+2.21%)
Volume$531.44K
Capitalization342.62M
XWELL
Price$1.12
Change-$0.08 (-6.67%)
Volume$2.37K
Capitalization7.06M
CERS vs XWEL Comparison Chart in %
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XWEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. XWEL commentary
Jul 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and XWEL is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 26, 2025
Stock price -- (CERS: $1.39 vs. XWEL: $1.12)
Brand notoriety: CERS and XWEL are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 45% vs. XWEL: 40%
Market capitalization -- CERS: $342.62M vs. XWEL: $7.06M
CERS [@Medical Specialties] is valued at $342.62M. XWEL’s [@Medical Specialties] market capitalization is $7.06M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileXWEL’s FA Score has 1 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • XWEL’s FA Score: 1 green, 4 red.
According to our system of comparison, XWEL is a better buy in the long-term than CERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while XWEL’s TA Score has 4 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 4 bearish.
  • XWEL’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both CERS and XWEL are a good buy in the short-term.

Price Growth

CERS (@Medical Specialties) experienced а +2.21% price change this week, while XWEL (@Medical Specialties) price change was +4.19% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +3.05%. For the same industry, the average monthly price growth was +5.16%, and the average quarterly price growth was -1.87%.

Reported Earning Dates

CERS is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+3.05% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than XWEL($7.06M). CERS YTD gains are higher at: -9.740 vs. XWEL (-20.530). XWEL has higher annual earnings (EBITDA): -17.82M vs. CERS (-26.34M). CERS has more cash in the bank: 65.9M vs. XWEL (26.1M). XWEL has less debt than CERS: XWEL (11.5M) vs CERS (96M). CERS has higher revenues than XWEL: CERS (156M) vs XWEL (30.3M).
CERSXWELCERS / XWEL
Capitalization343M7.06M4,856%
EBITDA-26.34M-17.82M148%
Gain YTD-9.740-20.53047%
P/E RatioN/AN/A-
Revenue156M30.3M515%
Total Cash65.9M26.1M252%
Total Debt96M11.5M835%
FUNDAMENTALS RATINGS
CERS vs XWEL: Fundamental Ratings
CERS
XWEL
OUTLOOK RATING
1..100
239
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
64
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6441
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/a27

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (43) in the Medical Specialties industry is in the same range as XWEL (64) in the Other Consumer Services industry. This means that CERS’s stock grew similarly to XWEL’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that CERS’s stock grew similarly to XWEL’s over the last 12 months.

CERS's SMR Rating (97) in the Medical Specialties industry is in the same range as XWEL (100) in the Other Consumer Services industry. This means that CERS’s stock grew similarly to XWEL’s over the last 12 months.

XWEL's Price Growth Rating (41) in the Other Consumer Services industry is in the same range as CERS (64) in the Medical Specialties industry. This means that XWEL’s stock grew similarly to CERS’s over the last 12 months.

XWEL's P/E Growth Rating (2) in the Other Consumer Services industry is significantly better than the same rating for CERS (100) in the Medical Specialties industry. This means that XWEL’s stock grew significantly faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSXWEL
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
76%
Bullish Trend 6 days ago
75%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XWEL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TTNP5.130.44
+9.46%
Titan Pharmaceuticals
TYRA10.78-0.03
-0.28%
Tyra Biosciences
NRG157.97-2.58
-1.61%
NRG Energy
HNVR22.10-0.44
-1.95%
Hanover Bancorp
GSAT24.93-1.17
-4.48%
Globalstar Inc

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
+2.21%
LAB - CERS
52%
Loosely correlated
-4.76%
BLFS - CERS
47%
Loosely correlated
+1.44%
NNOX - CERS
46%
Loosely correlated
N/A
CLPT - CERS
46%
Loosely correlated
-0.44%
ICUI - CERS
46%
Loosely correlated
+0.55%
More

XWEL and

Correlation & Price change

A.I.dvisor tells us that XWEL and LUCY have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XWEL and LUCY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XWEL
1D Price
Change %
XWEL100%
-3.61%
LUCY - XWEL
29%
Poorly correlated
-6.70%
DRIO - XWEL
28%
Poorly correlated
-4.04%
CERS - XWEL
22%
Poorly correlated
-6.21%
XRAY - XWEL
21%
Poorly correlated
-2.31%
MASI - XWEL
21%
Poorly correlated
-2.19%
More